BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Cellegy Pharmaceuticals (CLGY) Announces Completion Of Asset Sale To ProStrakan Group


11/29/2006 1:01:31 PM

QUAKERTOWN, Pa., Nov. 28 /PRNewswire-FirstCall/ -- Cellegy Pharmaceuticals, Inc. , a specialty pharmaceutical company, announced today the completion of the sale to Strakan International Limited, a wholly owned subsidiary of ProStrakan Group plc , a publicly-traded pharmaceutical company based in the United Kingdom, of Cellegy's rights to Cellegesic(TM) (nitroglycerin ointment), which is branded Rectogesic outside of the United States, Fortigel(TM) (testosterone gel), Tostrex(TM) (testosterone gel) and Tostrelle(R) (testosterone gel), and related intellectual property assets. ProStrakan also assumed various existing distribution and other agreements, including in certain Southeast Asian countries, relating to the assets and intellectual property that was sold. The signing of the asset purchase agreement was originally announced on September 27, 2006, and Cellegy's stockholders approved the transaction at a special meeting of stockholders held on November 22, 2006.

The aggregate purchase price was $9 million. From the sales proceeds, Cellegy paid ProStrakan approximately $2 million in repayment of a loan that ProStrakan had made to Cellegy at the time the asset purchase agreement was signed. Cellegy also paid $2,625,000 from the proceeds to PDI, Inc. and Neptune Pharmaceutical Corporation in final settlement of Cellegy's obligations under previous agreements with those companies.

Cellegy Pharmaceuticals, Inc.

CONTACT: Richard C. Williams, Chairman and Interim CEO, +1-215-529-6084,or Robert J. Caso, Vice President, Finance & CFO, +1-215-529-6084, both ofCellegy Pharmaceuticals, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES